SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ~~December~~June 3130, ~~2017~~2018
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________

Commission File Number: 000-54905

Cantabio Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-54905	99-0373067
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1250 Oakmead Pkwy Sunnyvale, California (Address of principal executive offices)		94085 (Zip Code)

844-200-2826

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☒
			Emerging Growth Company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes ☒ No

As of ~~February~~August ~~16th~~17, 2018, there were 3656,~~355~~510,~~468~~521 shares of the issuer’s common stock issued and outstanding.

CANTABIO PHARMACEUTICALS, INC

FORM 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	2
	Condensed Consolidated Balance Sheets as of December 31, 2017 and March 31, 2017	2
	Condensed Consolidated Balance Sheets as of June 30, 2018 and March 31, 2017	2
	Condensed Consolidated Statements of Operations for the three and nine months ended December 31, 2017 and 2016	3
	Condensed Consolidated Statements of Operations for the three months ended June 30, 2018 and 2017	3
	Condensed Consolidated Statements of Cash Flows for the three and nine months ended December 31, 2017 and 2016	4
	Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2018 and 2017	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	14
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
SIGNATURES		16

PART I – FINANCIAL INFORMATION

CANTABIO PHARMACEUTICALS, INC.

~~CONDENSED~~ CONSOLIDATED BALANCE SHEETS

(Unaudited)

	December 31,	March 31,
	June 30,	March 31,
	2017	2017
	2018	2018
ASSETS
Current Assets
Cash	$26185,~~774~~236	$32109,~~275~~426
Prepaid expenses	-	~~1,248~~-
Total Current Assets	26185,~~774~~236	33109,~~523~~426
TOTAL ASSETS	$26185,~~774~~236	$33109,~~523~~426
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses	~~672~~657,~~281~~871	~~377~~606,~~893~~751
Accrued technology access fee	~~163~~158,~~703~~968	~~140~~171,~~142~~105
Convertible debentures payable	723,000	322,256
Secured convertible debentures	1,371,126	947,160
Convertible debt related party	~~267~~300,~~922~~512	-257,614
Note payable related party	-	47,154
Total Current Liabilities	2,488,477	1,982,630
Total Current Liabilities	1,826,906	887,445
TOTAL LIABILITIES	$2,488,477	$1,982,630
TOTAL LIABILITIES	$1,826.906	$887,445
Stockholders' Equity (Deficit)
Commitments
Common stock, $0.001 par value, (250,000,000 shares authorized, 53.9 million and 51.9 million shares issued and outstanding as of June 30, 2018 and March 31, 2018, respectively)	53,864	51,857
Stockholders' equity (deficit)
Stock subscriptions	1,060,000	1,060,000
Common stock, $0.001 par value, (250,000,000 shares authorized, 30.4 and 26.8 million shares issued and outstanding as of December 31, 2017 and March 31, 2017 respectively)	30,396	26,805
Additional paid in capital	1,169,584	1,134,763
Stock Subscriptions	1,060,000	1,060,000
Accumulated deficit	(4,586,689)	(4,119,824)
Additional paid in capital	378,695	167,324
Total Stockholders' Equity (Deficit)	(2,303,241)	(1,873,204)
Accumulated deficit	(3,269,223)	(2,108,051)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$185,236	$109,426
Total Stockholders' Equity (Deficit)	(1,800,132)	(853,922)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$26,774	$33,523

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CANTABIO PHARMACEUTICALS, INC.

~~CONDENSED~~ CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended December 31,		For the nine months ended December 31,
	June 30, 2018	June 30,2017
	2017	2016	2017	2016
Operating Expenses
Operating expenses:
Research and development	$111,220	$97,192
Research & development	$58,480	$86,872	$254,576	$268,674
General & administrative	124,653	190,733
General & administrative	107,549	136,927	475,718	506,676
Total Operating Expenses	235,873	287,925
Total operating expenses	166,029	223,799	730,294	775,350
Loss From Operations	(235,873)	(287,925)
Loss from operations	(166,029)	(223,799)	(730,294)	(775,350)
Other Income & (Expenses)
Other income (expense):
Interest expense	(348,992)	(74,471)
Interest expense	(204,962)	(3,508)	(392,386)	(11,372)
Change in fair value of embedded derivatives, including modification accounting	118,000	10,000
Change in fair value of embedded derivatives	77,000	-	131,000	-
Total Other Income & (Expenses)	(230,992)	(64,471)
Loss on extinguishment of debt	(169,492)	-	(169,492)	-
Net Loss	$(466,865)	$(352,396)
Total other expense, net	(297,454)	(3,508)	(430,878)	(11,372)
Basic and Diluted Loss per share	$(0.01)	$(0.01)
Net loss	$(463,483)	$(227,307)	$(1,161,172)	$(786,722)
Weighted average number of common shares outstanding	53,031,199	27,004,613
Net loss per share - basic and diluted	$(0.02)	$(0.01)	$(0.04)	$(0.03)
Weighted average shares outstanding, basic and diluted	28,700,000	26,805,000	27,667,000	26,805,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CANTABIO PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended December 31
	Three Months Ended
	2017	2016
	June 30,	June 30,
	2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$(1466,~~161,172~~865)	$(~~786~~352,~~722~~396)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion to notes payable to related party	-	~~346~~1,266
Loss on extinguishment of debt	169,492	-
Amortization of debt discount	328,233	58,130
Amortization of debt discount	293,210	-
Change in fair value of embedded derivative	(118,000)	(10,000)
Change in fair value of embedded derivative	(131,000)	-
Share based compensation for services	10,000	39,549
Share based compensation for services	39,549	-
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	~~294~~51,~~390~~120	~~152~~87,~~017~~955
Accrued technology access fee	23(12,~~561~~137)	1110,~~026~~012
Accrued debenture interest	3418,~~721~~459	-10,062
Due to officers	-	~~(6,420)~~-
Prepaid Expenses	~~1,248~~-	~~---~~1,248
Net cash used in operating activities	(~~436~~189,~~001~~190)	(~~629~~154,~~753~~274)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible debt related party, net of issuance cost	~~175~~265,000	-127,000
Proceeds from issuance of convertible debenture, net of issuance cost	~~255,500~~-	-
Proceeds from notes payable related party	-	~~55,022~~-
Repayment to notes payable related party	-	~~(26,584)~~-
Share subscriptions	-	~~560,000~~-
Net cash provided by financing activities	~~430~~265,~~500~~000	~~588~~127,~~438~~000
Net increase (decrease) in cash	(575,~~501)~~810	(4127,~~315~~274)
Cash at beginning of period	32109,~~275~~426	5232,~~110~~275
Cash at end of period	$26185,~~774~~236	$105,~~795~~001
Schedule of non-cash financing activities
Recognition of beneficial conversion feature associated with convertible debentures	$~~35,000~~-	$-35,000
Conversion of Secured Convertible Debentures (Principal and Interest) into Common Shares	139,000	-
Conversion of secured convertible debentures	58,733	-
Share based compensation for services	10,000	39,549

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Cantabio Pharmaceuticals Inc. (the “Company” or “Cantabio”) is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from research and development activities for Parkinson’s disease (PD) and Alzheimer’s disease (AD). The Company’s strategy involves integration of therapeutic focus, the targeting of family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which synergizes to identify and develop small molecule pharmacological chaperones for clinical trials. In addition, the Company’s research efforts concentrate on the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins with display loss of function during disease conditions.

NOTE 2 – LIQUIDITY AND GOING CONCERN

As of ~~December~~June 3130, ~~2017~~2018, the Company had a working capital deficit of approximately $2.3 million and continues to have losses from operations due to its research and development activities.

The Company typically raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past the short-term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.

Management is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements. Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company for at least twelve months from issuance of these condensed consolidated financial statements.

The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~The~~Interim Company has developed the additional accounting policies below. Aside from these additions to the Company’s accounting policies there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on June 30, 2017.Reporting

~~Warrant~~The ~~Liability~~accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended March 31, 2018.

~~The~~Use Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of ~~operations.~~ The fair value of the warrants issued by the Company has been estimated using a valuation pricing model, at each measurement date that incorporates various inputs including remaining contractual term, stock volatility, risk free rate and dividend yield.Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.

Earnings (Loss) per Share

The Company calculates earnings per share using basic net income (loss) per common share be computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. The Company does not compute diluted earnings per share because to do so would be anti-dilutive.

~~Equity-linked~~CANTABIO ~~Financial~~PHARMACEUTICALS, ~~Instruments~~INC.

Certain of the Company’s debt instruments include embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815, Derivatives and Hedging. Under this guidance, the Company recognizes the embedded derivatives at fair value and records a gain or loss resulting from the change in fair values at the end of each reporting period. In connection with issuance of the Company’s Zhu Notes, ~~beginning on July 3, 2017, the Company became contingently obligated~~ to ~~issue~~Condensed ~~shares~~Consolidated ~~in excess~~Financial of the 250 million authorized by shareholders. Consequently, the ability to settle these obligations with shares would be unavailable causing these and other share-settled obligations to potentially be settled in cash.Statements

The Company applies a sequencing policy regarding share settlement wherein equity-linked financial instruments with the earliest issuance date would be settled first. Thus, all equity-linked financial instruments, which are convertible or exercisable into common stock, issued concurrent or subsequent to the Zhu Notes are classified as derivative liabilities, with the exception of instruments related to employee share-based compensation.(Unaudited)

~~Sequencing~~Potentially dilutive securities

As of July 3, 2017, the Company adopted a sequencing policy whereby all future equity-linked instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.

	June 30,	June 30,
	2018	2017
Convertible debentures (Note 6)	25,007,000	5,865,000
Convertible debt related party (Note 7)	5,908,000	-
Stock subscriptions	530,000	530,000

Income Taxes

The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.

In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that will affect the Company’s fiscal year ending March 31, 2018, including, but not limited to, reducing the U.S. federal corporate tax rate. The Tax Act reduces the federal corporate tax rate to 21 percent in the fiscal year ending March 31, 2018. Section 15 of the Internal Revenue Code stipulates that our fiscal year ending March 31, 2018, will have a blended corporate tax rate of approximately 21 percent, which is based on the applicable tax rates before and after the Tax Act and the number of days in the year. The reduction of the corporate tax rate will cause the Company to reduce its deferred tax asset to the lower federal base rate of 21% and adjust the allowance against the deferred tax asset by the same amount. The Company has not yet determined the impact the rate reduction will have on its gross deferred tax asset and liabilities and offsetting valuation allowance. The Company has a full allowance against the deferred tax asset and as a result there was no impact to income tax expense for the quarter ended December 31, 2017.

The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the company has utilized to calculate the transition impact. The Securities Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustments by the end of our current fiscal year ending March 31, 2018.

Recent Accounting Standards

Fiscal 2019 Accounting Pronouncement Adoptions

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and ~~beneficial~~ beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each ~~separately~~ separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard ~~will~~became be effective the Company for us on April 1, 2018. The ~~Company is currently evaluating the impact of this~~ new standard ~~and~~ does not ~~expect it to~~ have a material impact on our financial statements.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

In June 2018, the FASB issued Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 4 – RELATED PARTY TRANSACTIONS

~~Toth~~There ~~and~~have ~~Associates~~been ~~LTD~~no changes to the Company’s related party consulting arrangements as they have been disclosed in our most recently filed form 10K.

On July 1, 2016, the Company entered into a consulting agreement with Toth and Associates LTD for Dr. Toth to act as the Company’s CEO. The standard monthly fee is approximately $13,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event, (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any third party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement.

Capro LTD

On July 1, 2016, the Company entered a consulting agreement with Capro, LTD for Dr. Thomas Sawyer to act as the Company’s COO. The standard monthly fee is approximately $11,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any third party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement.

Eden Professional LTD

On July 1, 2016, the Company entered a consulting agreement with Eden Professional LTD for Mr. Simon Peace to act as the Company’s CFO. The standard monthly fee is approximately $7,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any third party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement.

CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Costs incurred associated with related party transactions noted above included in general and administrative in the statement of operations are as follows:

	For the three months ended December 31,		For the nine months ended December 31,
	For the three months ended June 30,
	2017	2016	2017	2016
	2018	2017
Operating expenses:
Toth and Associates LTD	$4044,000	$3640,000	~~$120,000~~	~~$108,000~~
Capro LTD	1824,000	3033,000	~~84,000~~	~~90,000~~
Eden Professional LTD	2123,000	1921,000	~~63,000~~	~~57,000~~
Max Zhu Consulting (1)	3,000	6,000	~~12,000~~	~~18,000~~
Total related party transactions	$8294,000	$91100,000	~~$279,000~~	~~$273,000~~

(1)

Max Zhu, an investor in and lender to the Company, also works as Head of Computer Aided Drug Design for the Company under a consultancy contract.

Accounts payable and accrued expenses includes amounts payable to related parties of $0.57 and $0.36 million for the period ended ~~December~~ 31June 30, ~~2017~~2018 and March 31, ~~2017~~2018, respectively.

NOTE 5 – CONVERTIBLE DEBENTURES AS AMENDED

~~Original~~ New issuance

~~The~~On June 5, 2018 the Company entered into ~~several~~a new securities purchase ~~agreements~~ agreement with an accredited investor to place Convertible Debentures (as amended the “Debentures”) in the aggregate principal amount of up to $~~750~~300,000 net of issuance costs of $35,000 (the “Transaction”),. ~~provided~~The ~~that~~Debentures inbear ~~case~~interest ofat anthe ~~event~~rate of ~~default,~~5% ~~the~~per ~~Debentures~~annum ~~may~~with ~~become at~~a ~~the~~maturity ~~holder’s~~date ~~election~~of ~~immediately~~June ~~due~~5, ~~and~~2019, ~~payable.~~as ~~The Debentures~~may ~~bear~~be ~~interest~~extended at the ~~rate~~option of the 5%note ~~per annum~~holder. In addition, the Company must pay to the holder aan annual fee equal to 7% of the amount of the Debentures to assist in their monitoring costs for the Debentures. The net proceeds of the financing were used for general corporate matters and for other expenses. The Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price.

~~Conversion~~At ~~Feature~~the same time all previous debentures were amended to align them with the new agreement. All the Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or (rather than $0.10 as previously) or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The Company accounted for the amendment as a debt modification which resulted in $76,000 impact that was recorded in the change in fair value of embedded derivatives in the Company’s statements of operations.

The Debentures may be converted at any time on or prior to maturity at the lower of $0.10 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The Debentures have been amended several times, including most recently in the third quarter with the floor price being $0.01 and the due date November 2018.

Monthly Redemption Feature

Any time after the six-month anniversary of the issuance of a Debenture that the daily VWAP is less than $0.01 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment begin deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.

In the third quarter a Triggering Date occurred and the Company recorded a premium of $50,000 included in accounts payable and accrued expense.

InCANTABIO ~~the third quarter the Company~~PHARMACEUTICALS, ~~entered into an amended agreement with the investor which included a change to the due date and an adjustment to the floor price~~INC. The terms of the new debt instrument was considered to be substantially different such that the changes were sufficient to recognize the amendment as an extinguishment of the debt. A loss on extinguishment of approximately $0.2 million was recorded in other income (expense). Debt discount of approximately $0.6 million was recorded as a result of the new issuance due to the conversion features.

~~Beneficial~~Notes ~~Conversion Feature~~to Condensed Consolidated Financial Statements

At the time of each closing, the Debenture’s effective conversion price was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion feature on each issuance date, resulting in a discount to the Debenture with a corresponding credit to additional paid-in capital.(Unaudited)

Embedded Derivatives

The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statements of Operations. The Company estimated the fair value of the monthly payment provision, as of the issuance date and ~~December~~June 3130, ~~2017~~2018 using probability analysis of of the occurrence of a Triggering Date applied to the ~~discounted~~ discounted maximum redemption premium for any given payment. The ~~probability~~ probability analysis utilized in calculating the embedded derivative upon issuance and at ~~December~~June 3130, ~~2017~~2018 was calculated using the following key inputs:

	Contingent Put
	June 30, 2018	March 31, 2018
Stock price	$0.0304	$0.06
Probability of Triggering Date	100%	100%
Volatility	~~282~~300%	300%
Risk-free rate	1%	1%
Discount rate	0%	0%

Due to the extinguishment of the notes and the Company’s sequencing policy the amended notes the Company recorded an embedded derivative associated with the conversion feature. The following are the inputs associated with the conversion feature.

	Conversion Feature
	June 30, 2018	March 31, 2018
Stock price	$0.0304 - $0.06	$0.06
Exercise price	$0.0304 - $0.06	$0.06
Volatility	~~282~~300%	300%
Contractual term	0.42 - 1 year	1 year
Risk-free rate	1%	1%
Discount rate	0%	0%

The fair value estimate of the embedded derivatives is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the ~~nine~~three months ended ~~December~~June 3130, ~~2017~~2018, is as follows:

Balance at March 31, 2017	Issuance	Net unrealized (gain)/loss	Balance at December 31, 2017
Balance at March 31, 2018	Issuance of new debentures	Change due to modification	Net unrealized (gain)/loss	Balance at June 30, 2018
24,000	$555,000	$131,000	$710,000
736,000	$281,000	$76,000	$(195,000)	$898,000

The approximate carrying value of the Debentures, as of ~~December~~June 3130, 2018 ~~2017~~and March 31, 2018 is comprised of the following:

Secured Convertible Debenture at December 31, 2017:
	June 30, 2018	March 31, 2018
Principal value of 5%, convertible	$633,000
Principal value of 5%, convertible, net of conversion	$1,000,000	$750,000
Fair value of embedded derivative	~~710~~898,000	736,000
Accrued interest	1423,000	22,264
Debt discount	(~~634~~550,000)	(561,104)
Carrying value of Secured Convertible Debenture Note	$~~723~~1,371,000	$947,160

As of ~~December~~June 3130, ~~2017~~2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $01.84 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.

~~During the current financial year, holders of approximately $0.1 million in principal amount and accrued interest with respect to Secured~~ Convertible ~~Debentures exercised the conversion option and converted into 3.3 million shares of common stock.~~debenture

During the three months ended June 30, 2018, holders of approximately $0.1 million in principal amount and accrued interest with respect to Secured Convertible Debentures exercised the conversion option and converted into 1.6 million shares of common stock.

Events of Default or Financial covenants

The Company is in compliance with all terms associated with the convertible note.

CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 6 – CONVERTIBLE DEBT RELATED PARTY

InThe ~~the~~analysis ~~second~~utilized ~~quarter~~in ofcalculating ~~fiscal 2018~~ the ~~Company~~embedded ~~issued~~derivative ~~convertible~~at ~~notes~~June ~~payable~~30, to2018 ~~Max~~and ~~Zhu~~March ~~for an aggregate principal balance of $220~~31,~~000,~~ in2018 ~~exchange~~was ~~for~~calculated ~~cash~~using ~~of $175,000 and~~ the ~~exchange of a~~following ~~note~~key ~~payable to Mr. Zhu with a principal balance of $45,000. The extinguished notes payable was fully matured.~~inputs:

The convertible notes payable have a six-month term and incurs interest at rates ranging from 18% to 23% through maturity. If the notes are not repaid within the six-month term, the interest rate increases on each note to rates ranging from 23% to 28%. The Company has the option to settle the principal and all accrued interest of each note in cash or shares.

	June 30, 2018	March 31, 2018
Stock price	$0.04	$0.02- $0.07
Contractual term	0.1 - 0.5 years	0.1 - 1.0 years
Volatility	300%	275% - 300%
Risk-free rate	1%	1%

The ~~note~~fair ~~holder~~value ~~has~~estimate ~~the right to convert all or any portion~~ of the ~~outstanding~~ ~~principal~~embedded ~~and~~derivative ~~accrued~~is ~~interest~~a ofLevel ~~each note into common~~3 ~~shares~~measurement. ofThe ~~the~~roll-forward ~~Company at a conversion price~~ of the ~~lesser~~Level ~~of:~~3 ~~(i) $0.08~~fair ~~per share~~value measurement, orfor ~~(ii) a price equal to 80% of~~ the ~~lowest~~three ~~VWAP during~~months ~~the~~ended ~~five~~June ~~consecutive~~30, ~~days~~2018, ~~before~~is ~~the notice of~~as ~~conversion.~~follows:

Upon issuance of the convertible notes, the Company recognized an aggregate debt discount of approximately $0.2 million relating to the bifurcated embedded conversion option.

Balance at March 31, 2018	Net unrealized (gain)/loss	Balance at June 30, 2018
$156,000	$(1,000)	$157,000

The ~~analysis~~carrying ~~utilized~~value inof ~~calculating~~ the ~~embedded~~Notes, ~~derivative~~as ~~upon issuance~~of ~~and~~June at30, ~~December~~2018 and March 31, 2018 ~~2017~~is ~~was~~comprised ~~calculated~~of ~~using~~ the ~~following~~ ~~key inputs~~following:

	Key Inputs
	June 30, 2018	March 31, 2018
Stock price	$0.01- $0.03
Principal value of 5%, convertible	$220,000	$220,000
Contractual term	0.1 - 0.5 years
Fair value of embedded conversion option	157,000	156,000
Volatility	125%-159%
Accrued Interest	23,704	15,204
Risk-free rate	1%
Debt discount	(100,192)	(133,590)
Carrying value of Secured Convertible Debenture Note	$300,512	$257,614

~~The~~As of June 30, 2018, the estimated aggregate fair value ~~estimate~~ of outstanding ~~the~~convertible ~~embedded~~notes ~~derivative~~payable is aapproximately ~~Level 3~~$0.2 ~~measurement~~million. The ~~roll-forward~~fair ofvalue ~~the~~estimate ~~Level~~is 3based ~~fair~~on ~~value~~the estimated option ~~measurement,~~value ~~for~~of the ~~nine~~conversion ~~months~~terms. ~~ended~~The ~~December~~estimated ~~31,~~fair ~~2017,~~value ~~is as~~represents ~~follows:~~a Level 3 measurement.

Balance at Issuance	Net unrealized (gain)/loss	Balance at December 31, 2017
159,000	$(90,000)	$69,000

The carrying value of the Notes, as of December 31, 2017, is comprised of the following:

Secured Convertible Debenture at December 31, 2017:
Principal value of 5%, convertible	$220,000
Fair value of embedded conversion option	69,000
Accrued Interest	16,740
Debt discount	(37,818)
Carrying value of Secured Convertible Debenture Note	$267,922

As of December 31, 2017, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.3 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.

Technical default

The notes which are due in January 2018 are in technical default, although the obligation has not been called by the lender. The note agreement provided for such circumstances with the effect that the Company ~~will~~is ~~record~~currently accruing the interest at the default interest rate of 23 28%.

CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 7 – CAPITAL STOCK

Issuance of shares for consulting services.

~~Through~~During ~~December~~the 31three months ended June 30, ~~2017~~2018 the Company issued approximately 0.3 4 million shares with a fair value of approximately $4010,000 as compensation for services performed.

Potentially dilutive securities

	December 31,		March 31,
	2017		2017
Potentially dilutive securities
Convertible debentures (Note 6)		26,375,000		3,420,000
Convertible debt related party (Note 7)		10,577,000		-

NOTE 8 – SUBSEQUENT EVENTS

On ~~Jan~~July 826, 2018 ~~the~~a ~~Board~~holder ~~agreed~~of a convertible ~~debt~~debentures ~~deal with Max~~converted ~~Zhu~~approximately ~~for~~ $~~120,000~~0.1 onmillion ~~terms~~of ~~similar~~principal toand ~~those~~interest ~~for prior deals, except~~into ~~for~~approximately ~~the~~2.6 ~~addition~~million ofshares ~~the floor price~~ of ~~$0.01.~~common ~~The note is due July 2018~~stock.

On Jan 12, 2018 the Company issued approximately 6 million shares to Max Zhu following conversion of two earlier loans totalling $120,000 principle plus approximately $15,000 interest.

On February 15, 2018, the Company received $150,000 less fees and costs representing the second tranche of funding under the securities purchasing agreement dated November 20, 2017.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report.

This Quarterly Report contains forward-looking statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based on information currently available. The expectations indicated by such forward-looking statements might not be realized. If any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations should materialize, our actual results may differ materially from those indicated by the forward-looking statements.

The key factors that are not within our control and that may have a direct bearing on operating results include, but are not limited to, managements’ ability to raise capital in the future, the retention of key employees and changes in the regulation of our industry. There may be other risks and circumstances that management may be unable to predict.

When used in this Quarterly Report, words such as, "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.

As of ~~December~~June 3130, ~~2017~~2018, we had approximately $27185,000 cash in the bank. This amount will not satisfy our cash requirements for the next twelve months. We plan to satisfy our future cash requirements by additional equity financing. This will likely be in the form of private placements of common stock. Additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.

If we are unsuccessful in raising the additional proceeds through a private placement offering, we will then have to seek capital from other sources such as debt financing, which may not be available to us. However, if such financing were available, we would likely have to pay additional costs associated with high risk loans and be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such debt financing and determine whether the business could manage the debt load. If we cannot raise additional proceeds via a private placement of our common stock or secure debt financing we would be required to cease as a business. As a result, investors in our common stock would lose all of their investment.

Results of Operations for the three months ended ~~December~~June 3130, ~~2017~~2018, as as compared to the three months ended ~~December~~June 3130, ~~2016~~ 2017.

Our operating expenses decreased to $~~166~~235,~~029~~873 for the three months ended ~~December~~June 3130, ~~2017~~2018 from $~~223~~287,~~799~~925 in the three months ended ~~December~~ 31June 30, ~~2016~~2017. The R&D spend of $58111,~~480~~220 in the three months to ~~December 31~~June 30, ~~2017~~2018 compares with $8697,~~872~~192 on R&D in the same period in ~~2016~~ 2017, the ~~decrease~~increase being due toadditional ~~most~~spend ~~R&D~~on ~~activity taking place in house in the period rather than using~~ third party contract research organisations. There was a decrease of approximately $3066,000 in General and Administrative to $~~107~~124,~~549~~653 in the three months to ~~December~~June 3130, ~~2017~~2018 from $~~136~~190,~~927~~733 in the three ~~months~~ months to ~~December~~June 3130, ~~2016~~2017. The decrease was largely driven by decreased legal and professional fees related to fundraising activities inand ~~2016~~decreased ~~and~~investor byrelations ~~careful management of other expenses~~spend.

We generated Other Expense in the three months ended ~~December~~June 3130, ~~2017~~ 2018 of $~~297~~230,~~454~~992 made up of $~~204~~348,~~962~~992 of interest expense, the overwhelming majority of which relates to amortization of debt discount connected with convertible instruments, and a $~~169~~118,~~492 loss~~000 ~~upon extinguishment of debt, partially offset by a~~ gain ~~of $77,000 due to change~~ in fair value of an embedded derivative. Other Expense for the same period of ~~2016~~2017 was $364,~~508~~471, made up of was $74,471 of interest expense, onpartially offset by a $10,000 gain in fair value of an ~~loans~~embedded derivative.

Results of Operations for the nine months ended December 31, 2017, as compared to the nine months ended December 31, 2016.

Our operating expenses decreased to $730,294 for the nine months ended December 31, 2017 from $775,350 in the nine months ended December 31, 2016. R&D spend of $254,576 in the nine months to December 31, 2017, compared to $268,674 in the same period in 2016, was driven by lower third-party R&D costs. There was a decrease in General and Administrative expenses to $475,718 in the nine months to December 31, 2017 from $506,676 in the same period in 2016 largely driven by lower legal and professional fees.

Other Expense in the nine months ended December 31, 2017 was $430,878 made up of $392,386 of interest expense the majority of which relates to amortization of debt discount connected with convertible instruments, and a loss upon extinguishment of debt of $169,492 offset by a gain of $131,000 due to change in fair value of an embedded derivative. Other Expense for the same period of 2016 was $11,372 of interest on loans.

Liquidity and Capital Resources

On ~~December~~June 3130, ~~2017~~2018, we had approximately $26185,~~774~~000 in current assets, ~~consisting~~ consisting entirely of cash. Our total current liabilities as of June ~~December~~30, 312018, ~~2017,~~ were approximately $12,~~826~~488,~~906~~000. Thus, we had negative working capital of approximately $12,~~800~~303,~~132~~000 as of ~~December~~June 3130, ~~2017~~ 2018.

Cash Flows from Financing Activities. During the ~~nine~~three months ended ~~December~~June 3130, ~~2017~~2018, financing activities provided $~~430~~265,~~500,~~000 ~~comprised~~from ~~of $255,500 through~~ a convertible debenture ~~facility, and $175,000 through~~ ~~convertible loan facilities~~facility. This compares to approximately $~~590~~127,000 ~~during~~from ~~the~~a convertible ~~same~~debenture ~~period~~facility ~~last year, comprised of $560,000 raised~~ in ~~funds~~the ~~for~~same ~~issuance~~period ~~of future equity, offset by net~~in ~~proceeds of debt of approximately $26,000~~2017.

The Company typically raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past, the short-term nature of these funding cycles raises substantial risk around the Company's ability to continue as a going concern.

Our financial statements indicate there is substantial doubt about our ability to continue as a going concern as this would depend upon our ability to obtain ongoing financing and ultimately to generate sufficient cash flow to meet our obligations on a timely basis. Our plans and efforts to achieve the above steps might not be successful, which raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.

OFF BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

A set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in the reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms is required to be maintained by management. Disclosure controls should be designed with the objective of ensuring that this information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management has not designed and currently does not maintain a designed set of disclosure controls and procedures.

We have not evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. As a result, management has concluded that our disclosure controls and procedures were not effective for the year ended ~~December~~June 3130, ~~2017~~2018, due to the following:

Failure to design and maintain a set of disclosure and control procedures

Lack of segregation of duties as a result of limited personnel.

Lack of Functioning Audit Committee - We do not have an Audit Committee, our board of directors currently acts as our Audit Committee. We do not have an independent director.

PART II: OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On ~~July~~April 330, ~~2017~~2018, ~~the~~a ~~Company~~holder ~~entered~~of ~~into~~ a convertible ~~debt~~debenture converted ~~arrangement~~$58,733 ~~with~~of ~~Max~~interest ~~Zhu~~and ~~for~~principal ~~$75,000~~on ~~and~~such ~~amended~~debenture aninto ~~existing loan~~1,636,013 shares of ~~$45,000~~our tocommon bestock ~~upon~~at ~~the~~$0.0359 ~~same~~per ~~terms~~share aspursuant ~~the~~to ~~July 3, 2017~~the ~~convertible~~terms ~~debt~~of ~~arrangement~~such debenture.

On ~~August~~May 3112, ~~2017~~2018, ~~the~~we ~~Company~~issued ~~entered~~370,370 ~~into~~shares aof ~~further~~our ~~convertible~~common stock to a ~~debt~~supplier ~~arrangement~~in ~~with~~satisfaction ~~Max~~of ~~Zhu~~invoices ~~for~~worth $~~100~~10,000.

~~The~~On ~~conversion~~July of26, ~~all~~2018, ~~these~~a ~~loans~~holder ~~shall~~of ~~be at~~ a ~~price~~convertible ~~which~~debenture ~~is the~~converted ~~lower~~$51,192 of ~~$0.08~~interest ~~per share~~ and ~~80%~~principal ofon ~~the~~such ~~lowest~~debenture ~~calculated~~into 2,646,937 ~~volume-weighted~~shares ~~average price~~ of ~~the~~our common stock ~~during~~at ~~the five days before the date of the conversion notice~~$0.01934 Weper ~~made~~share ~~these~~pursuant ~~issuances in~~to ~~reliance on~~ the ~~registration exemption provided by Section~~ ~~4(a)(2)~~terms of ~~the~~such ~~Securities Act of 1933, as amended~~debenture.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None.

Item 6. Exhibits

31.1	Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
32.1	Certification of the Principal Executive Officer and Acting Principal Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 101

101.INS - XBRL Instance Document

101.SCH - XBRL Taxonomy Extension Schema Document

101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF - XBRL Taxonomy Extension Definition Linkbase Document

101.LAB - XBRL Taxonomy Extension Label Linkbase Document

101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cantabio Pharmaceuticals Inc.

By: /s/ Gergely Toth

Gergely Toth

Its: President, Chief Executive Officer, Director (Principal Executive Officer).

~~February~~August 20, 2018

By: /s/ Simon Peace

Simon Peace

Its: Chief Financial Officer, Director (Principal Accounting Officer)

~~February~~August 20, 2018

Filing Compare · Cantabio Pharmaceuticals Inc.